Analysts Offer Predictions for ARCT FY2026 Earnings

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) – Cantor Fitzgerald issued their FY2026 EPS estimates for shares of Arcturus Therapeutics in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst P. Stavropoulos expects that the biotechnology company will earn ($3.06) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Arcturus Therapeutics’ current full-year earnings is ($2.22) per share.

A number of other research analysts have also commented on the stock. Wall Street Zen upgraded shares of Arcturus Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, May 22nd. Citigroup reiterated a “buy” rating on shares of Arcturus Therapeutics in a research note on Tuesday, May 13th. HC Wainwright reiterated a “buy” rating and issued a $60.00 price target on shares of Arcturus Therapeutics in a research note on Thursday, April 10th. Scotiabank assumed coverage on shares of Arcturus Therapeutics in a research note on Wednesday, May 28th. They issued a “sector outperform” rating and a $32.00 price target on the stock. Finally, BTIG Research set a $48.00 price target on shares of Arcturus Therapeutics and gave the company a “buy” rating in a research note on Monday, March 10th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $53.50.

Arcturus Therapeutics Stock Performance

Shares of ARCT opened at $12.90 on Tuesday. Arcturus Therapeutics has a 52 week low of $8.04 and a 52 week high of $34.17. The firm has a market cap of $349.86 million, a P/E ratio of -5.81 and a beta of 2.30. The firm’s 50-day simple moving average is $11.55 and its 200 day simple moving average is $14.53.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its earnings results on Monday, May 12th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.58) by $1.06. The company had revenue of $29.38 million for the quarter, compared to analysts’ expectations of $25.64 million. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Wellington Management Group LLP grew its position in shares of Arcturus Therapeutics by 0.8% during the 4th quarter. Wellington Management Group LLP now owns 97,036 shares of the biotechnology company’s stock worth $1,647,000 after purchasing an additional 742 shares in the last quarter. Ameriprise Financial Inc. grew its position in shares of Arcturus Therapeutics by 5.0% during the 4th quarter. Ameriprise Financial Inc. now owns 18,613 shares of the biotechnology company’s stock worth $316,000 after purchasing an additional 883 shares in the last quarter. Tocqueville Asset Management L.P. grew its position in shares of Arcturus Therapeutics by 4.5% during the 1st quarter. Tocqueville Asset Management L.P. now owns 23,400 shares of the biotechnology company’s stock worth $248,000 after purchasing an additional 1,000 shares in the last quarter. Virtus ETF Advisers LLC grew its position in shares of Arcturus Therapeutics by 38.8% during the 4th quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 1,132 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its position in shares of Arcturus Therapeutics by 9.2% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 14,693 shares of the biotechnology company’s stock worth $156,000 after purchasing an additional 1,232 shares in the last quarter. Institutional investors and hedge funds own 94.54% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.